Director Williams Gregg of Vivani Medical, Inc. (NASDAQ:VANI) executed a purchase of 1,587,301 shares of common stock on April 15, 2026, at $1.26 per share, bringing the transaction value to $1,999,999. After the trade, Gregg directly holds 4,799,200 shares and indirectly holds 32,944,484 shares.
The company’s shares are trading at $1.14, which is below the director’s purchase price, even as the stock has posted a 9.62% gain over the last week. Independent Fair Value calculations cited in market analysis indicate that VANI appears overvalued at current levels, and observers note that the stock has remained notably volatile.
Financing to support research
Vivani Medical recently completed a $4.5 million equity financing intended to fund its research programs. The company sold a total of 1,689,200 shares of common stock at $1.48 per share through a registered direct offering together with a concurrent private placement. In the private placement portion, Gregg Williams, who serves as Chairman of Vivani’s board, purchased 1,351,351 shares at the $1.48 price.
The financing was explicitly framed as support for Vivani’s ongoing clinical-stage biopharmaceutical research.
Clinical progress reported by subsidiary
Cortigent, a Vivani Medical subsidiary, disclosed positive six-year results for its Orion Visual Cortical Prosthesis System. The system is designed to provide visual perception to blind individuals, and the study reported safety and efficacy outcomes. These results were presented at the North American Neuromodulation Society annual meeting.
Context and implications
The combination of a meaningful insider purchase, a completed equity raise, and multi-year clinical data from a subsidiary underscores Vivani’s dual focus on capitalizing research and advancing medical-device development. Market commentary that flags an overvaluation and notes volatility provides a counterpoint to the company’s operational updates, including the reported clinical findings for the Orion system.
Given the data presented and the financing activity, observers will likely continue to watch share-price movements, the capital plan for clinical programs, and any subsequent disclosures about Cortigent’s prosthesis study results.